RE: NIAID results31 Jan 2024 14:29
I sent an email yesterday to the company, strange or just coincidence that they replied to me last night and issued an RNS this morning....H'mm
Dear Mr XXXX,
Thank you for your email. I appreciate your frustration regarding the awaited update on pre-clinical results for XF-73 dermal. As is usual, there have been final process-related steps to complete in conjunction with NIAID, ahead of release of the pre-clinical data. We intend to update the market on these results as soon we are able, and in full compliance with our obligations under the AIM rules. I appreciate your patience and support for the company.
Kind regards
Shaun Claydon, Chief Financial Officer, Destiny Pharma plc
Destiny Pharma plc
Sussex Innovation Centre
Science Park Square
Falmer, Brighton, UK
BN1 9SB